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Abstract
We previously observed association between variants in the plasmacytoma variant translocation 1 gene (PVT1) and end-
stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes, and demonstrated PVT1 expression in a variety of
renal cell types. While these findings suggest a role for PVT1 in the development of ESRD, potential mechanisms for
involvement remain unknown. The goal of this study was to identify possible molecular mechanisms by which PVT1 may
contribute to the development and progression of diabetic kidney disease. We knocked-down PVT1 expression in mesangial
cells using RNA interference, and analyzed RNA and protein levels of fibronectin 1 (FN1), collagen, type IV, alpha 1 (COL4A1),
transforming growth factor beta 1 (TGFB1) and plasminogen activator inhibitor-1 (SERPINE1 or PAI-1) by qPCR and ELISA,
respectively. PVT1 expression was significantly upregulated by glucose treatment in human mesangial cells, as were levels of
FN1, COL4A1, TGFB1, and PAI-1. Importantly, PVT1 knockdown significantly reduced mRNA and protein levels of the major
ECM proteins, FN1 and COL4A1, and two key regulators of ECM proteins, TGFB1 and PAI-1. However, we observed a higher
and more rapid reduction in levels of secreted FN1, COL4A1, and PAI-1 compared with TGFB1, suggesting that at least some
of the PVT1 effects on ECM proteins may be independent of this cytokine. These results indicate that PVT1 may mediate the
development and progression of diabetic nephropathy through mechanisms involving ECM accumulation.
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Introduction
Diabetic nephropathy is the most common cause of chronic
renal failure in developed countries and accounts for most of the
reduced life expectancy in individuals with diabetes [1]. The
prevalence of ESRD attributed to diabetes is increasing, mainly
due to the rising prevalence of type 2 diabetes mellitus (T2D), and
the decreasing age of T2D onset [1,2]. Despite the growing
magnitude of the disease, the molecular mechanisms underlying
the etiology of diabetic nephropathy remain poorly understood.
Risk factors for diabetic nephropathy include duration of diabetes,
glycemic control, hypertension, and hyperlipidemia [3,4]; howev-
er, genetic factors are also strong determinants of disease risk
[5,6,7]. Correspondingly, results from genome-wide association
studies to identify loci for diabetic kidney disease are now
becoming available in the literature [8,9,10,11], but at the present
time, the clinical relevance of these, and other genetic findings,
awaits additional validation and functional characterization to
identify the molecular mechanisms by which these genes impact
upon disease pathophysiology.
We previously utilized a genome-wide SNP genotyping
approach to identify loci underlying susceptibility to ESRD
attributed to T2D, and found the strongest evidence for
association with variants in the gene encoding plasmacytoma
variant translocation 1 or PVT1 [9]. We later validated this locus
in a replication study comprised of individuals with ESRD
attributed to T1D, and demonstrated PVT1 expression in a
number of diverse renal cell types [12]. PVT1 is located on 8q24,
and in humans, is well known for its participation in recurrent
translocations between this region and chromosomes 2 and 22
[13,14]. The first exon of the gene is co-amplified with MYC in
colon carcinoma cell lines [15], and overexpression of PVT1 also
contributes to ovarian and breast cancer [16]. Although the PVT1
locus encodes a number of alternative transcripts, no PVT1 protein
product has yet been identified. Instead, PVT1 likely represents a
non-coding RNA that, when amplified and over-expressed,
increases cell proliferation and inhibits apoptosis [16].
While the relationship between PVT1 and certain forms of
cancer has been firmly established, the role that this gene may play
in mediating the development of kidney disease in diabetes is
presently not known. However, it is well-recognized that excessive
accumulation of extracellular matrix in the glomeruli is a hallmark
of diabetic nephropathy. Mesangial cells (MC) play a central role
in the development of diabetic nephropathy because they regulate
glomerular filtration rate (GFR) through their contractility [17,18]
and produce the ECM proteins that accumulate in the glomerular
mesangium of patients with diabetic nephropathy [19,20].
Mesangial expansion impinges on glomerular capillaries, reducing
the surface available for filtration and narrowing or occluding the
lumen, and it is widely held that these mesangial changes are one
of the main causes of declining renal function in diabetic
nephropathy [21]. In light of this background, we decided to
initiate the functional characterization of PVT1 in the kidney by
first investigating its role in mesangial cells.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18671Based on the findings of association between variants in PVT1
and diabetic ESRD, and expression in different cells of the kidney,
we sought to obtain biological evidence to support a role for this
gene in the disease process. The goal of this study, therefore, was
to identify possible molecular mechanisms by which PVT1 may
contribute to the development and progression of diabetic
nephropathy in mesangial cells. We first determined the extent
to which PVT1 expression is regulated by glucose in the kidney,
and because diabetic nephropathy is characterized by excessive
accumulation of extracellular matrix (ECM) in the glomeruli, we
also assessed the effect of glucose on mRNA and protein
expression of specific ECM components in relation to PVT1 in
mesangial cells. Finally, as a first step toward characterizing the
role of PVT1 in the accumulation of ECM proteins in MC, we
examined the effect of PVT1 knockdown using RNA interference
on mRNA and protein expression of these components under high
glucose conditions.
Results
Effect of glucose on expression of PVT1 and ECM-related
proteins
We first investigated the effect of glucose on the expression of
PVT1 in (MC). As shown in Fig. 1A, PVT1 expression levels in MC
were increased at all time points under high glucose (HG: 30 mM)
compared to normal glucose (NG: 5.6 mM) or 3-O-MG (OC:
5.6 mM glucose+24.4 mM 3-O-MG) conditions; the highest
increase was seen at 96 hours (Fig. 1A). Because diabetic
nephropathy is characterized by excessive accumulation of ECM
in the glomeruli, we also assessed the effect of glucose on mRNA
expression of the two main components of ECM in MC: FN1 and
COL4A1, and found increases of FN1 expression at 48 h, 72 h,
and 96 h, but not at 24 h. COL4A1 mRNA levels were also
significantly higher under HG versus NG or OC conditions at
72 h and 96 h, but not at 24 h or 48 h (Fig. 1A). The mRNA
levels for all the analyzed ECM-related genes expressed in MC
under NG conditions for 0 h (basal conditions) were used as
calibrator in the qPCR analysis and arbitrarily set to 1. We
observed that the ECM-related mRNA levels in MC under NG for
24 h, 48 h, 72 h and 96 h are not significantly different from NG
at 0 h (data not shown). In Fig. 1A, we arbitrarily set to 1 the
mRNA levels for all the ECM-related genes analyzed in MC
under NG conditions for 0 h, 24 h, 48 h, 72 h and 96 h.
We next quantified FN1 and COL4A1 protein concentrations
in media from MC cultured for 48 h, 72 h or 96 h under NG,
HG, or OC conditions (PVT1 is a non-coding RNA and, therefore,
has no protein product to quantify). As shown in Fig. 1B, the FN1
secreted by MC in HG conditions progressively increased from
70% higher than NG or OC at 48 h to 110% higher than NG or
OC at 96 h of incubation, in agreement with the progressive
increase of FN1 mRNA from 30% to 40% at 48 h and 96 h,
respectively (Fig. 1A). The increase of secreted COL4A1 was 30%
and 25% higher in MC under HG compared to NG or OC
conditions at 72 h and 96 h of incubation, respectively. However,
Figure 1. Effect of glucose on expression of PVT1, FN1, and
COL4A1 in normal human mesangial cells (MC). Prior to treatment
with high glucose, MC, at approximately 70% confluence, were cultured
in serum-free MsBM medium for 24 hours to arrest and synchronize cell
growth. After this time period, MC were grown for 24, 48, 72 or 96 h in
MsBM medium supplemented with 5% FBS, containing either normal
glucose (NG; 5.6 mM), NG+3-O-methyl-D-glucose (3-O-MG) to control
for osmotic effects (OC: 5.6 mM glucose+24.4 mM 3-O-MG) or high
glucose (HG: 30 mM). (A) Relative quantification of PVT1, FN1 and
COL4A1 mRNA by TaqMan qPCR. The mRNA level for all the genes was
arbitrary set to 1 under NG conditions at each time point. Data are
presented as mRNA fold-increase incubated under HG or NG conditions.
Quantification of secreted FN1 (B) and COL4A1 (C) proteins by ELISA.
Data are expressed as nanograms of FN1 or COL4A1 per total soluble
protein (TSP). Results represent average of three independent
experiments. Data are means 6 SD. A.U.: arbitrary units. * P,0.05;
** P,0.01; *** P,0.001 with respect to NG at each time point.
doi:10.1371/journal.pone.0018671.g001
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COL4A1 in HG versus NG or OC conditions at 48 h (Fig. 1C),
which is concordant with levels of COL4A1 mRNA incubated in
HG vs. NG or OC for 24 h and 48 h (Fig. 1A).
Because TGFB1 is a key mediator of ECM accumulation in
diabetic nephropathy, and PAI-1 inhibits ECM turnover, we also
examined the effect of glucose on expression of these genes. As
shown in Fig. 2A, TGFB1 mRNA expression was 0.15-fold and
1.35-fold higher under HG versus NG conditions at 72 h and
96 h, respectively. PAI-1 mRNA expression was increased
approximately 0.5-fold under HG versus NG conditions at all
time points (Fig. 2A). The mRNA levels for all the analyzed ECM-
related genes expressed in MC under NG conditions for 0 h (basal
conditions) were used as calibrator in the qPCR analysis and
arbitrarily set to 1. We observed that the ECM-related mRNA
levels in MC under NG for 24 h, 48 h, 72 h and 96 h are not
significantly different from NG at 0 h (data not shown). In Fig. 2A,
we arbitrarily set to 1 the mRNA levels for all the ECM-related
genes analyzed in MC under NG conditions for 0 h, 24 h, 48 h,
72 h and 96 h. We next quantified levels of secreted TGFB1 and
PAI-1 protein in media from MC cultured for 48, 72 or 96 h
under NG, HG, or OC conditions. Levels of secreted TGFB1
were 10%, 20% and 40% higher under HG versus NG or OC
conditions at 48 h, 72 h, and 96 h, respectively (Fig. 2B). Levels of
secreted PAI-1 were 35%, 50% and 115% higher under HG
compared to NG or OC conditions at the same time points
(Fig. 2C).
Effect of PVT1 knockdown on mRNA and protein
expression of FN1 and COL4A1
To determine the role of PVT1 in the accumulation of ECM
proteins in MC, we depleted PVT1 gene expression using RNA
interference techniques under HG conditions and quantified levels
of PVT1, FN1 and COL4A1 mRNA levels by qPCR. We observed
a 0.6-fold, 0.7-fold and 0.85-fold decrease in PVT1 mRNA levels
in MC transfected with PVT1 siRNAs compared to those
transfected with Neg siRNA at 48 h, 72 h and 96 h post-
transfection, respectively. In addition, siRNA knockdown of
PVT1 expression was accompanied by a 0.3 and 0.4-fold decrease
of FN1 and COL4A1 mRNA expression, respectively (Fig. 3A).
Correspondingly, levels of secreted FN1 (Fig. 3B) and COL4A1
(Fig. 3C) were also significantly reduced after PVT1 knockdown in
MC under HG conditions, to the basal levels found in MC under
NG conditions (grey bars).
Effect of PVT1 knockdown on mRNA and protein
expression of TGFB1 and PAI-1
We also analyzed TGFB1 and PAI-1 mRNA levels by qPCR
and their secreted protein products by ELISA in MC transfected
with PVT1 siRNAs. As shown in Fig. 4A, levels of TGFB1 mRNA
were decreased 0.3-fold and 0.8-fold in MC transfected with PVT1
siRNAs at 72 h, and 96 h compared to cells transfected with Neg
siRNA or non-transfected cells (Fig. 4A). Levels of secreted
TGFB1 were decreased by 20%, and 15% at the same time points,
respectively (Fig. 4B). We observed a much greater 30–35%
decrease in mRNA (Fig. 4A) and 50–60% decrease in secreted
protein (Fig. 4C) levels of PAI-1 in MC transfected with PVT1
siRNA compared to Neg siRNA or non-transfected cells. The
levels of secreted TGFB1 (Fig. 4B) and PAI-1 (Fig. 4C) were
Figure 2. Effect of glucose on TGFB1 and PAI-1 expression in
MC. (A) Relative quantification of TGFB1 and PAI-1 mRNA by TaqMan
qPCR. The mRNA level for all the genes was arbitrary set to 1 under NG
conditions at each time point. Data are presented as mRNA fold-
increase in MC incubated in HG or NG OC conditions. Quantification of
secreted TGFB1 (B) and PAI-1 (C) proteins by sandwich ELISA. Data are
expressed as picograms of PAI-1 or TGFB1 per total soluble protein
(TSP). Results represent average of three independent experiments.
Data are means 6 SD. A.U.: arbitrary units. * P,0.05; ** P,0.01;
*** P,0.001 with respect to NG at each time point.
doi:10.1371/journal.pone.0018671.g002
PVT1 and Diabetic Nephropathy
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18671significantly reduced after PVT1 knockdown in MC under HG
conditions, to the basal levels found in MC under NG conditions.
Discussion
We first identified PVT1 as a candidate gene for ESRD using a
genome-wide SNP association study in American Indians with
T2D [9], and later validated this locus in an independent group of
individuals with T1D [12]. Findings of expression in different cell
types of the kidney provided preliminary evidence that PVT1 may
influence metabolic dysregulation in this tissue preceding the
development of renal failure in diabetes. Here, we provide
additional biological evidence supporting a role for PVT1 in the
pathogenesis of diabetic nephropathy.
In the current study, we found that PVT1 expression levels
increase up to 5-fold in response to hyperglycemic conditions,
showing an effect of glucose on PVT1 regulation. Reduction of
PVT1 expression by siRNA significantly affected mRNA and
protein levels of all ECM components examined, suggesting that
PVT1 contributes to ECM deposition in the glomeruli, one of the
major pathological features of diabetic nephropathy.
One of the more important findings of this work was that PVT1
effects on expression of FN1, COL4A1, and PAI-1 may be
mediated independently of TGFB1, a well-known profibrotic
factor which promotes tissue fibrosis by upregulating genes
encoding ECM proteins in response to hyperglycemia [20]. In
our study, we found a higher and more rapid decrease in FN1,
COL4A1 and PAI-1 compared to TGFB1 in response to PVT1
knockdown. Specifically, at 48 hours following PVT1 knockdown,
no significant effect on secreted TGFB1 was apparent, yet levels of
secreted FN1, COL4A1, and PAI-1 were already decreased by
50%, 30%, and 60%, respectively. Further, during the time course
when PVT1 expression was decreased 60–85%, there was a 40–
60% decrease in secreted FN1, PAI-1, and COL4A1, but only a
20% reduction in TGFB1. It is reasonable to expect that if the
effect of PVT1 were mediated only by TGFB1, then a
correspondingly low decrease (i.e., 20%) in secreted FN1,
COL4A1, and PAI-1 would be observed. These findings suggest
that PVT1 may regulate expression of ECM proteins in a manner
that is, at least in part, independent of TGFB1 (Fig. 5). Delineation
of the relationship between TGFB1 and PVT1 therefore represents
a critical component toward understanding the molecular
mechanisms underlying the regulation of ECM in diabetic
nephropathy.
In addition to these findings, we also observed effects of high
glucose treatment on expression of ECM-related factors in
mesangial cells. Although increased secretion of FN1, COL4A1,
TGFB1 and PAI-1 has been previously noted [22,23,24,25], there
are substantial disparities in the literature regarding the timing and
magnitude of the increase in secreted ECM-related proteins by
MC following glucose induction (for example, see
[22,25,26,27,28,29]). Differences among studies may reflect the
utilization of different cell lines, cell culture media components,
and concentrations of glucose used for induction, as well as the
level of sensitivity and specificity associated with each of the
Figure 3. Effect of PVT1 knockdown on the expression of FN1
and COL4A1. (A) PVT1, FN1 and COL4A1 mRNA levels following
transfection of MC with PVT1 siRNA. Data were obtained by qPCR
analysis and presented as mRNA fold-increase compared with Neg
siRNA. Non-transfected (NT) MC were used as a second negative
control. Quantification of secreted FN1 (B) and COL4A1 (C) in media
from MC. Data were obtained by sandwich ELISA and compared with
Neg siRNA. White and grey bars represent non-transfected (NT) MC
under HG and NG conditions, respectively; black and striped bars
represent MC under HG conditions transfected with Neg or PVT1 siRNA,
respectively. Results represent average from three independent
experiments. Data are means 6 SD. A.U.: arbitrary units. * P,0.05;
** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0018671.g003
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found in the literature, we therefore sought to characterize the
quantification of ECM accumulation in response to glucose in the
particular cell line and conditions comprised in this study.
Interestingly, we found significant increases in levels of secreted
FN1 and PAI-1 at 48 h, 72 h and 96 h (Fig. 1B and 2C), as well as
COL4A1 and TGFB1 at 72 h and 96 h (Fig. 1C and 2B), which
contrasts with results reported by Wahab et al. [28] and Tada
et al. [27], who did not detect increased levels of collagen type IV
or PAI-1, respectively, following exposure of primary human MC
to HG. However, our results are in agreement with Isono et al.
[30], who found a 20% increase in secreted TGFB1 at 72 h in
human MC. Interestingly, Oh et al. [26] reported an early
increase in TGFB1 mRNA at 6 h in rat MC under HG conditions,
which was not observed in humans, and may reflect a species-
specific expression response. Although there is ample discrepancy
in expression patterns of FN1, COL4A1, PAI-1, and TGFB1 in
MC in response to HG among different reports, for the current
study, we are confident that the methods utilized here, TaqMan
qPCR and sandwich ELISA, are among the most sensitive and
specific to quantify mRNA and proteins, respectively, thus,
ensuring the accuracy of our findings.
To date, most investigations of PVT1 have been conducted in
respect to cancer, particularly lymphomas and breast/ovarian
Figure 5. Potential mechanism for PVT1 involvement in ECM
deposition. Hyperglycemia causes an excessive accumulation of
extracellular matrix (ECM) in the glomerular mesangium which
constitutes the major pathological feature of the glomerulosclerosis
or glomerular fibrosis. Hyperglycemic conditions induce an increase in
PVT1 expression in MC which contributes to the increase of the two
main ECM components, FN1 and COL4A1, as well as the two main
regulators of ECM accumulation in the glomerule, PAI-1 and TGFB1. PAI-
1 is the main inhibitor of glomerular ECM degradation and TGFB1
promotes glomerular fibrosis by upregulating genes encoding ECM
proteins and PAI-1. PAI-1 and TGFB1 transcriptionally regulate each
other creating a vicious cycle of reciprocal stimulation that perpetuates
the fibrotic response. PVT1 may contribute to ECM accumulation mainly
through a TGFB1-independent mechanism (see text). FN1: fibronectin 1;
COL4A1: alpha 1, type IV, collagen; PAI-1: plasminogen activator
inhibitor; TGFB1: transforming growth factor beta 1.
doi:10.1371/journal.pone.0018671.g005
Figure 4. Effect of PVT1 gene knockdown on TGFB1 and PAI-1.
(A) PVT1, TGFB1 and PAI-1 mRNA levels following MC transfection with
PVT1 siRNA. Data were obtained by qPCR analysis and presented as
mRNA fold-increase compared with Neg siRNA. Non-transfected (NT)
MC were used as a second negative control. Quantification of secreted
TGFB1 (B) and PAI-1 (C) in media from MC after cell transfection with
PVT1 siRNAs. Data were obtained by sandwich ELISA and compared
with Neg siRNA. White and grey bars represent non-transfected (NT) MC
under HG and NG conditions; black and striped bars, MC under HG
conditions transfected with Neg or PVT1 siRNA, respectively. Results
represent the average of three independent experiments. Data are
means 6 SD. A.U.: arbitrary units. * P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0018671.g004
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humans, PVT1 has been shown to play a role in cell proliferation
and apoptosis, and it is likely that the tumorigenic properties of
PVT1 are manifested, at least in part, through this activity. How
might PVT1, a gene that does not appear to encode a protein
product, contribute to the dysregulation of ECM production? One
possibility is through the actions of small, non-coding microRNA
molecules (miRNA). miRNAs are short, non-coding RNAs that
typically bind the 39-UTR of target mRNAs, leading to
posttranscriptional silencing and translational repression
[31,32,33,34], RNA degradation [35,36,37], or transcriptional
inhibition [38]. miRNAs have been widely studied in cancer,
where they can act as oncogenes or tumor suppressors [39,40], but
they have also been associated with the regulation of genes
involved with insulin secretion, cholesterol biosynthesis, fat
metabolism, and adipogenesis [41,42,43]. Importantly, miRNAs
have been shown to mediate TGFB signaling in diabetic
nephropathy, and several candidates, including miR-92, miR-
192, miR-216a, miR-217, and miR-377 are upregulated in
mesangial cells in response to either glucose or TGFB, and are
also indirectly correlated with increased collagen and fibronectin
expression [44,45,46,47]. For example, Wang et al. [47]
demonstrated that miR-377 leads to reduced expressions of p21-
activated kinase and superoxide dismutase, which enhanced
fibronectin protein production. Thus, overexpression of miR-377
in diabetic nephropathy indirectly leads to increased fibronectin
protein production.
There are at least 6 known miRNAs mapping to the PVT1
locus, including miR-1204, -1205, -1206, -1207-5p, 1207-3p, and -
1208 [48], and it is possible that some of the effects of PVT1 on
ECM factors may be mediated through a miRNA mechanism.
Whether PVT1-derived miRNAs act in concert with, or indepen-
dent from, those previously identified miRNAs remains to be seen;
however, our preliminary findings suggest that miR-1205, miR-
1207-3p, miR-1207-5p, and miR-1208 are up-regulated by high
glucose in mesangial cells (data not shown). Additional character-
ization of PVT1-derived miRNAs will be required to fully delineate
the relationship between PVT1 and changes in ECM-related
proteins.
Despite the evidence showing involvement of PVT1 in ECM
regulation, we acknowledge several issues that may limit the
interpretation of our findings. First, the experiments presented
here were performed in primary human mesangial cells and thus,
conclusions drawn from the results presented here are necessarily
limited to this cell type. We chose to initiate the functional
characterization of PVT1 in this cell type because one of the key
hallmarks of diabetic nephropathy is expansion of mesangium.
Mesangial cells are directly involved in the expansion of the
mesangium, which is comprised of mesangial cells and extracel-
lular matrix, and the extent to which we could pinpoint a role for
PVT1 in this process would determine the direction in which
further studies could be designed. However, we recognize that
PVT1 may play a general role among different cell types, including
podocytes, renal proximal tubule cells, and others.
Another limitation is our focus on the effect of PVT1 on ECM-
related processes, although this gene may likely be involved in
other biological pathways, including cell proliferation and
apoptosis (67). PVT1 may also regulate other ECM components
and key ECM regulators not addressed in this study, particularly
those detected mainly in late glomerulosclerosis (21), including
collagen type I and III, matrix metalloproteinases MMP3, MMP7,
MMP10 and MMP1 [49], as well as the proteoglycans, decorin,
versican, and perlecan [20]. Given the findings obtained here, the
study of additional PVT1 targets involved with ECM, is well-
justified.
In conclusion, the results presented here provide biological
support for findings of association with ESRD in individuals with
T1D and T2D. We show that PVT1 is regulated by hyperglyce-
mia, and may mediate susceptibility to diabetic kidney disease
through effects involving ECM accumulation. Further character-
ization of this gene may yield potentially new insight into disease
pathogenesis, and additional investigations of the role of PVT1 in
the kidney are therefore warranted.
Methods
Mesangial cell culture
Primary cultures of normal human mesangial cells (MC) were
purchased from Lonza (Walkersville, MA) and cultured in Lonza
Mesangial Cell Basal Medium (MsBM) supplemented with 5%
fetal bovine serum (FBS) according to the manufacturer’s
instructions. Briefly, approximately 3500 cells/cm
2 were seeded
in 25 cm
2 cell culture flasks (Corning Life Sciences; Lowell, MA)
containing 5 ml of Lonza Mesangial Cell Basal Medium (MsBM)
supplemented with 5% fetal bovine serum (FBS). Cells were placed
at 37uC in a Hera Cell 5% CO2 incubator (ThermoFisher
Figure 6. Position of the two PVT1 siRNAs, PVT1a and PVT1-tv6, used for transfection of mesangial cells. The SNP with the highest
association with ESRD in type 1 diabetes, rs13447075, is shown as a vertical line next to the PVT1-tv6 siRNA. Bottom, chromosome distance
coordinates in kb from National Center for Biotechnology Information Build 37.1 of the PVT1 locus.
doi:10.1371/journal.pone.0018671.g006
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day after MC seeding, and then again every two days. Cells were
subcultured every 7 to 9 days using Clonectis ReagentPack
Subculture Reagents (Lonza; Walkersville, MA) according to the
manufacturer’s instructions. All experiments were performed using
cells between the sixth and eighth passage.
Total RNA extraction and quantification
Total RNA was extracted using the RNeasy Plus Mini Kit
(Qiagen; Valencia, CA) according to the manufacturer’s instruc-
tions. RNA concentration was determined by absorbance at
260 nm and RNA integrity was evaluated using the RNA 6000
Nano Lap Chip Kit; only RNA samples with a RIN.8 and 18S/
28S ratio .2.0 were used in the qPCR assays.
Quantitative real-time RT-PCR (qPCR)
First-strand cDNA was synthesized from total RNA obtained
from mesangial cells using random primers and the Super Script
III Reverse Transcriptase kit (Invitrogen) according to the
manufacturer’s protocol. Quantitative real time RT-PCR (qPCR)
was performed using commercial TaqMan Gene Expression
Assays (Applied Biosystems; Foster City, CA) in conjunction with
the ABI Prism 7900 HT Sequence Detector apparatus (Applied
Biosystems). Data were normalized using both PPIA (cyclophilin A)
and UBC (ubiquitin C), the 2 most stable housekeeping genes
tested for the experimental conditions used. Results were analyzed
with RQ Manager software (Applied Biosystems), and qBasePlus
v1.5 (Biogazelle NV; Ghent, Belgium). Assay information is
provided in the Table S1.
Protein extraction and quantification
Cell culture media from MC was treated with 0.5 ml absolute
ethanol/ml of media for a final 33% v/v ethanol and stored at
220uC for at least 2 hours to precipitate proteins. Samples were
then centrifuged at 4,0006g for 30 min at 4uC, and the protein
precipitate was resuspended in 400 ml of PBS supplemented with
Complete Protease Inhibitor Cocktail (Roche; Indianapolis, IN).
Total protein content for each sample was determined using the
BCA Protein Assay kit (Pierce; Rockford, IL) according to the
manufacturer’s instructions.
Enzyme-linked immunosorbent assay analysis (ELISA)
Protein concentration was determined using a commercial
sandwich ELISA kit for TGFB1 (R&D Systems; Minneapolis,
MN) and PAI-1 (eBiosciences; San Diego, CA), or competitive
inhibition ELISA for FN1 (Millipore; Billerica, MA) according to
the manufacturer’s instructions. COL4A1 was quantified using an
indirect ELISA developed in our laboratory. For this assay, total
soluble protein was extracted from cell culture media as described
above, and extracts were incubated overnight at 4uC in high bind
polystyrene EIA 96 wells microplates (Corning Life Sciences),
followed by three washes with PBST (PBS plus 0.05% Tween 20),
and blocking with 1% bovine serum albumin (BSA) in PBST
(blocking buffer) for 2 h at room temperature. After another three
washes with PBST, rabbit anti-COL4A1 polyclonal antibody
(Abcam; San Francisco, CA) was added at a 1:1000 dilution in
blocking buffer, and incubated for 2 h at room temperature. After
another three washes with PBST, the plate was incubated with
peroxidase-labeled goat anti-rabbit (Bio-Rad; Hercules, CA) at a
1:1000 dilution in blocking buffer, and final detection was
performed using TMB peroxidase substrate (Bio-Rad). The
reaction was stopped after 5 min with 1N H2SO4, and the optical
density was read at 450 nm using a VICTOR3 Microplate Reader
(Perkin Elmer; Waltham, MA).
PVT1 knockdown using small interfering RNA (siRNA) in
MC
A mixture of two siRNAs targeting different parts of PVT1 were
used in this study: PVT1a siRNA targets exon 2 and has been
shown to knockdown PVT1 [16], and PVT1-tv6 siRNA (Fig. 6),
which was designed from Accession number BG110543 using
Dharmacon siDesign (www.dharmacon.com). The target sequence
of PVT1-tv6 siRNA was 59-GCATGGACTTGCAGGCCAA-39.
The EST BG110543 contains marker rs13447075, which was
previously found to be associated with ESRD [12]. Approximately
2610
5 MC were plated per 25 cm
2 flask at least 24 h before
transfection to achieve 50–70% confluency, then transfected with
either 60 nM PVT1a siRNA+PVT1-tv6 siRNA, or negative
control siRNA comprised of sequence not found in the human
genome (Applied Biosystems; Foster City, CA), using 5 ml
Lipofectamine RNAiMax (Invitrogen; Carlsbad, CA) per ml of
MsBM media following the manufacturer’s instructions. Cells and
cell culture media were harvested 48, 72, and 96 h post-
transfection for RNA and protein analysis, respectively.
Statistical analysis
All statistical analyses were performed using the software Graph
Pad Prism 5 for Microsoft Windows. One-way ANOVA test with a
Dunnett’s Multiple Comparison post-test were used to assess
differences between conditions. Results were considered statisti-
cally significant if P,0.05.
Supporting Information
Table S1
(DOC)
Acknowledgments
We thank Dr. Christopher Kingsley for helpful discussions.
Author Contributions
Conceived and designed the experiments: MLA JKD. Performed the
experiments: MLA. Analyzed the data: MLA. Wrote the paper: MLA
JKD.
References
1. U.S.R.D.S. (2002) United States Renal Data System Annual Data Report: Atlas
of End-Stage Renal Disease in the United States. Bethesda: National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases. pp
296–322.
2. Jones CAKA, Rogus J, Xue JL, Collins A, Warram JH (2005) Epidemic of end-
stage renal disease in people with diabetes in the United States population: Do
we know the cause? Kidney Int 67: 1684–1691.
3. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH (1995) Incidence
and determinants of elevated urinary albumin excretion in Pima Indians with
NIDDM. Diabetes Care 18: 182–187.
4. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main
risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol
levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:
998–1004.
5. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990) Familial
predisposition to renal disease in two generations of Pima Indians with type 2
(non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438–443.
6. Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors
determine the development of diabetic nephropathy in patients with IDDM.
Diabetologia 39: 940–945.
PVT1 and Diabetic Nephropathy
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e186717. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic
kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.
N Engl J Med 320: 1161–1165.
8. Craig DW, Millis MP, DiStefano JK (2009) Genome-wide SNP genotyping
study using pooled DNA to identify candidate markers mediating susceptibility
to end-stage renal disease attributed to Type 1 diabetes. Diabet Med 26:
1090–1098.
9. Hanson RL, Craig DW, Millis MP, Yeatts KA, Kobes S, et al. (2007)
Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in
Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide
Polymorphism Association Study. Diabetes 56: 975–983.
10. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, et al.
(2009) Genome-wide association scan for diabetic nephropathy susceptibility
genes in type 1 diabetes. Diabetes 58: 1403–1410.
11. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, et al. (2005)
Genetic Variations in the Gene Encoding ELMO1 Are Associated With
Susceptibility to Diabetic Nephropathy. Diabetes 54: 1171–1178.
12. Millis MP, Bowen D, Kingsley C, Watanabe RM, Wolford JK (2007) Variants in
the plasmacytoma variant translocation gene (PVT1) are associated with end-
stage renal disease attributed to type 1 diabetes. Diabetes 56: 3027–3032.
13. Graham M, Adams JM (1986) Chromosome 8 breakpoint far 39 of the c-myc
oncogene in a Burkitt’s lymphoma 2;8 variant translocation is equivalent to the
murine pvt-1 locus. Embo J 5: 2845–2851.
14. Mengle-Gaw L, Rabbitts TH (1987) A human chromosome 8 region with
abnormalities in B cell, HTLV-I+ T cell and c-myc amplified tumours. Embo J
6: 1959–1965.
15. Shtivelman E, Bishop JM (1989) The PVT gene frequently amplifies with MYC
in tumor cells. Mol Cell Biol 9: 1148–1154.
16. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, et al. (2007) Amplification
of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin
Cancer Res 13: 5745–5755.
17. Ausiello DA, Kreisberg JI, Roy C, Karnovsky MJ (1980) Contraction of cultured
rat glomerular cells of apparent mesangial origin after stimulation with
angiotensin II and arginine vasopressin. J Clin Invest 65: 754–760.
18. Blantz RC, Konnen KS, Tucker BJ (1976) Angiotensin II effects upon the
glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest
57: 419–434.
19. Haneda M, Koya D, Isono M, Kikkawa R (2003) Overview of glucose signaling
in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14: 1374–1382.
20. Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic
nephropathy. J Am Soc Nephrol 14: 1358–1373.
21. Steffes MW, Osterby R, Chavers B, Mauer SM (1989) Mesangial expansion as a
central mechanism for loss of kidney function in diabetic patients. Diabetes 38:
1077–1081.
22. Ayo SH, Radnik RA, Glass WF, 2nd, Garoni JA, Rampt ER, et al. (1991)
Increased extracellular matrix synthesis and mRNA in mesangial cells grown in
high-glucose medium. Am J Physiol 260: F185–191.
23. Haneda M, Kikkawa R, Horide N, Togawa M, Koya D, et al. (1991) Glucose
enhances type IV collagen production in cultured rat glomerular mesangial cells.
Diabetologia 34: 198–200.
24. Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN (1998) Transcriptional activation
of transforming growth factor-beta1 in mesangial cell culture by high glucose
concentration. Kidney Int 54: 1107–1116.
25. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, et al. (2005) Reactive oxygen
species mediate high glucose-induced plasminogen activator inhibitor-1 up-
regulation in mesangial cells and in diabetic kidney. Kidney Int 67: 1762–1771.
26. Oh JH, Ha H, Yu MR, Lee HB (1998) Sequential effects of high glucose on
mesangial cell transforming growth factor-beta 1 and fibronectin synthesis.
Kidney Int 54: 1872–1878.
27. Tada H, Tsukamoto M, Ishii H, Isogai S (1994) A high concentration of glucose
alters the production of tPA, uPA and PAI-1 antigens from human mesangial
cells. Diabetes Res Clin Pract 24: 33–39.
28. Wahab NA, Harper K, Mason RM (1996) Expression of extracellular matrix
molecules in human mesangial cells in response to prolonged hyperglycaemia.
Biochem J 316(Pt 3): 985–992.
29. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN (1992) High glucose-
induced proliferation in mesangial cells is reversed by autocrine TGF-beta.
Kidney Int 42: 647–656.
30. Isono M, Cruz MC, Chen S, Hong SW, Ziyadeh FN (2000) Extracellular signal-
regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose
in mesangial cells. J Am Soc Nephrol 11: 2222–2230.
31. Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, et al. (2007) MicroRNA
silencing through RISC recruitment of eIF6. Nature 447: 823–828.
32. Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, et al.
(2007) An mRNA m7G cap binding-like motif within human Ago2 represses
translation. Cell 129: 1141–1151.
33. Maroney PA, Yu Y, Fisher J, Nilsen TW (2006) Evidence that microRNAs are
associated with translating messenger RNAs in human cells. Nat Struct Mol Biol
13: 1102–1107.
34. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA (2006) Short RNAs repress
translation after initiation in mammalian cells. Mol Cell 21: 533–542.
35. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R (2005) MicroRNA-
dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell
Biol 7: 719–723.
36. Rossi JJ (2005) RNAi and the P-body connection. Nat Cell Biol 7: 643–644.
37. Sen GL, Blau HM (2005) Argonaute 2/RISC resides in sites of mammalian
mRNA decay known as cytoplasmic bodies. Nat Cell Biol 7: 633–636.
38. Kim DH, Saetrom P, Snove O, Jr., Rossi JJ (2008) MicroRNA-directed
transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A
105: 16230–16235.
39. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136: 215–233.
40. Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat
Rev Mol Cell Biol 10: 126–139.
41. Heneghan HM, Miller N, Kerin MJ (2010) Role of microRNAs in obesity and
the metabolic syndrome. Obes Rev 11: 354–361.
42. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. (2004) A pancreatic
islet-specific microRNA regulates insulin secretion. Nature 432: 226–230.
43. Poy MN, Spranger M, Stoffel M (2007) microRNAs and the regulation of
glucose and lipid metabolism. Diabetes Obes Metab 9 Suppl 2: 67–73.
44. Kato M, Arce L, Natarajan R (2009) MicroRNAs and their role in progressive
kidney diseases. Clin J Am Soc Nephrol 4: 1255–1266.
45. Kato M, Putta S, Wang M, Yuan H, Lanting L, et al. (2009) TGF-beta activates
Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN.
Nat Cell Biol 11: 881–889.
46. Kato M, Zhang J, Wang M, Lanting L, Yuan H, et al. (2007) MicroRNA-192 in
diabetic kidney glomeruli and its function in TGF-beta-induced collagen
expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104:
3432–3437.
47. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, et al. (2008) MicroRNA-377 is
up-regulated and can lead to increased fibronectin production in diabetic
nephropathy. Faseb J 22: 4126–4135.
48. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, et al. (2008) The
identification of microRNAs in a genomically unstable region of human
chromosome 8q24. Mol Cancer Res 6: 212–221.
49. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, et al. (2000)
Effects of glucose on matrix metalloproteinase and plasmin activities in
mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 77:
S81–87.
PVT1 and Diabetic Nephropathy
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18671